SEATTLE, WASHINGTON – Sound Pharmaceuticals, a private biotechnology firm, has announced the successful completion of enrollment in its second Phase 3 open-label study for SPI-1005, an investigational oral therapy targeting Ménière’s disease (MD). This significant milestone brings the company closer to potentially introducing the first approved treatment specifically designed for this debilitating inner ear disorder, which currently lacks disease-modifying therapeutic options. The development follows SPI-1005’s receipt of the coveted FDA Breakthrough Therapy Designation in late 2025, underscoring its potential to address a profound unmet medical need.
The completion of enrollment for this open-label study, which saw 191 participants recruited across nine U.S. clinical sites over an eight-month period, is a crucial step in the regulatory pathway for SPI-1005. Its primary objective was to gather comprehensive safety data to support chronic daily dosing, a critical consideration for a condition like Ménière’s disease that often requires long-term management. This study, alongside three other clinical trials, has collectively enrolled a total of 578 adults diagnosed with probable or definite Ménière’s disease, marking the largest cohort of participants in an investigational new drug (IND) trial for MD in the past decade. This extensive clinical program highlights Sound Pharmaceuticals’ deep commitment to rigorous evaluation and its leadership in addressing complex neurotologic indications.
Ménière’s disease is a chronic and progressive disorder of the inner ear characterized by a constellation of distressing symptoms including episodic vertigo (a severe spinning sensation), fluctuating low- to mid-frequency sensorineural hearing loss, tinnitus (ringing or buzzing in the ear), and aural fullness. The unpredictable nature and severity of these attacks can significantly impair a patient’s quality of life, leading to substantial physical and psychological distress, and often resulting in long-term disability. While its exact etiology remains elusive, theories range from endolymphatic hydrops (excess fluid in the inner ear) to inflammatory processes and genetic predispositions. Current management strategies are largely symptomatic, focusing on diet modifications, diuretics, vestibular suppressants, or, in severe cases, intratympanic injections of steroids or gentamicin, and surgical interventions, none of which offer a consistent, disease-modifying cure. The absence of an FDA-approved drug specifically for Ménière’s disease underscores the urgency and significance of SPI-1005’s development.
SPI-1005: A Novel Approach to Inner Ear Disorders
At the heart of SPI-1005’s therapeutic promise is ebselen, a synthetic organoselenium compound that functions as a new chemical entity (NCE). Ebselen’s unique mechanism of action involves mimicking and inducing the activity of glutathione peroxidase (GPx), a critical enzyme within the body’s antioxidant defense system. Specifically, GPx1 plays a vital role in protecting cells from oxidative stress by catalyzing the reduction of harmful reactive oxygen species, such as hydrogen peroxide and organic hydroperoxides, into less damaging substances. This process is essential for maintaining cellular integrity and function, particularly in metabolically active tissues like the inner ear, retina, prefrontal cortex of the brain, lungs, and kidneys.
In conditions like Ménière’s disease, as well as noise-induced hearing loss and ototoxicity caused by certain medications, cellular injury and aging are often exacerbated by increased oxidative stress and subsequent neuroinflammation. These "environmental insults" can lead to a reduction in endogenous GPx activity, creating a vicious cycle that perpetuates cell damage and dysfunction. By boosting GPx activity, SPI-1005 aims to mitigate this oxidative damage and neuroinflammation, thereby potentially halting or reversing the progression of inner ear pathology and its associated symptoms. This targeted approach represents a paradigm shift from current symptomatic treatments, offering the potential for a disease-modifying therapy.
The FDA’s decision to grant SPI-1005 Breakthrough Therapy Designation for Ménière’s disease in late 2025 was a pivotal moment. This designation is reserved for drugs that treat a serious or life-threatening condition and where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies on one or more clinically significant endpoints. For SPI-1005, this means the FDA recognized compelling early data suggesting its potential to offer significant benefits to patients suffering from Ménière’s. The Breakthrough Therapy pathway facilitates an expedited development and review process, offering sponsors intensive guidance from the FDA, including organizational commitment, and eligibility for rolling review, where portions of the marketing application can be submitted as they are completed. This accelerated pathway reflects the high medical need and the promising efficacy signals observed in earlier studies. Notably, SPI-1005 is not only the first drug to receive this designation for Ménière’s disease but also for the broader category of sensorineural hearing loss.
A Robust Clinical Development Program
Sound Pharmaceuticals’ clinical program for SPI-1005 has been extensive and multifaceted. Prior to the recently completed Phase 3 open-label study, the drug demonstrated favorable safety and efficacy results in a Phase 2 randomized controlled trial (RCT) evaluating its potential for acute noise-induced hearing loss. A separate Phase 2 RCT also showed positive outcomes in cases of aminoglycoside-induced ototoxicity, a severe side effect of certain antibiotics that can lead to permanent hearing loss and balance issues. These earlier successes in different neurotologic indications provided a strong foundation for advancing SPI-1005 into late-stage trials for Ménière’s disease.
The comprehensive assessment of sensorineural hearing loss in these trials relies on standardized audiological testing, including pure-tone audiometry (PTA) to measure hearing thresholds across different frequencies, and speech discrimination testing, such as the Words-in-Noise (WIN) test. These objective measures are critical for accurately diagnosing and monitoring the progression of hearing loss and other auditory dysfunctions, providing quantifiable data on SPI-1005’s impact.
Dr. Jonathan Kil, Co-Founder and CEO of Sound Pharmaceuticals, expressed significant optimism regarding the future of SPI-1005. "We look forward to advancing SPI-1005 as the first approved treatment for Meniere’s later this year and early next year," he stated. This forward-looking statement underscores the company’s confidence in the clinical data and its ambitious timeline for regulatory submission and potential market introduction.
Broader Therapeutic Potential and Patient Impact
The therapeutic applications of SPI-1005 extend beyond Ménière’s disease. Its ability to modulate GPx activity positions it as a promising candidate for several other neurotologic indications where oxidative stress and neuroinflammation play a significant role. These include:
- Noise-induced hearing loss and tinnitus: Chronic or acute exposure to loud noise is a leading cause of sensorineural hearing loss and tinnitus, conditions often linked to oxidative damage in the cochlea.
- Aminoglycoside-induced ototoxicity: Certain antibiotics, such as tobramycin and amikacin, can cause severe and often irreversible damage to the hair cells of the inner ear, leading to hearing loss, tinnitus, dizziness, or vertigo. SPI-1005 offers a potential preventative or mitigating strategy.
- Platinum-based chemotherapy-induced ototoxicity: Chemotherapeutic agents like cisplatin and carboplatin, while effective against cancer, are notorious for causing ototoxicity, particularly in pediatric patients and those receiving high doses. SPI-1005 could offer a protective mechanism for these vulnerable populations.
To date, the safety profile of SPI-1005 appears favorable, with no significant drug-drug interactions observed across multiple study populations, including those with Ménière’s disease, cystic fibrosis, bipolar mania, and treatment-resistant depression. This broad safety record across diverse patient groups is encouraging for its potential widespread use. Cumulatively, fifteen ongoing and completed SPI-1005 trials have enrolled over 980 patients, with an additional 200+ patients anticipated to be enrolled over the next year across its various indications. This extensive clinical footprint reflects the company’s comprehensive development strategy and the versatility of ebselen’s mechanism of action.
The Landscape of Ménière’s Disease and Future Outlook
Ménière’s disease affects an estimated 0.2% of the population, translating to hundreds of thousands of individuals in the United States alone. Its unpredictable nature, combined with the severity of vertigo attacks, can lead to significant functional disability, social isolation, and an increased risk of accidents. The economic burden includes direct healthcare costs, lost productivity, and the emotional toll on patients and their families. The potential approval of SPI-1005 could revolutionize the treatment landscape, offering patients a much-needed oral, disease-modifying therapy that targets the underlying pathology rather than merely managing symptoms.
Sound Pharmaceuticals, as a private biotechnology company, has strategically focused its resources on SPI-1005, operating under five active Investigational New Drug (IND) applications for various neurotologic indications. The company’s disciplined approach to clinical development, culminating in the significant enrollment numbers achieved, positions it as a leader in addressing challenging inner ear disorders.
The next steps for Sound Pharmaceuticals involve the meticulous analysis of the data collected from this recently completed Phase 3 open-label study, particularly concerning long-term safety. Following this, the company will compile a comprehensive New Drug Application (NDA) for submission to the FDA. Given the Breakthrough Therapy Designation, the review process is expected to be expedited. If approved, SPI-1005 would represent a monumental advancement for patients with Ménière’s disease, offering hope for improved quality of life and potentially slowing or preventing disease progression. The broader implications for other forms of sensorineural hearing loss and ototoxicity also suggest a significant impact on audiological medicine and public health. The medical community and patient advocacy groups will be keenly watching for further updates as Sound Pharmaceuticals moves closer to bringing this potentially transformative therapy to market.
Detailed information regarding the SPI-1005 clinical trials is publicly accessible online at www.clinicaltrials.gov and www.soundpharma.com. For further inquiries, Sound Pharmaceuticals can be contacted directly at [email protected].
Source: Sound Pharmaceuticals via Business Wire.
